IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction
JACC: Heart Failure（2022）
摘要
Higher IGFBP-7 in patients with HFrEF was associated with worse clinical profile and an increased risk of adverse clinical outcomes. IGFBP-7 provided prognostic information incremental to clinical variables, NT-proBNP, and hsTnT. The benefit of dapagliflozin was not modulated by IGFBP-7 level. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124).
更多查看译文
关键词
SGLT2 inhibitor,biomarker,dapagliflozin,heart failure,insulin-like growth factor–binding protein-7
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要